Drug Database
AL

aluminium hydroxide (Pangramin Depot)

✓ Approved

ALK-Abello · therapeutic agent

What is aluminium hydroxide?

aluminium hydroxide is a therapeutic agent developed by ALK-Abello. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand NamesPangramin Depot
CompanyALK-Abello
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, ALK-Abello

Therapeutic Indications

aluminium hydroxide is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Respiratory, thoracic and mediastinal disordersRhinitis allergic✓ Approved

Related Research Articles

PubMedCurrent opinion in oncology2026-09-19

Precision medicine for pediatric gliomas.

Baroni Lorena V LV, Bouffet Eric E

The fifth edition of the WHO Classification of Tumors of the Central Nervous System marked a paradigm shift from predominantly histopathological classification toward integrated molecular-pathological definitions. This review summarizes the contemporary molecular landscape of pediatric gliomas, pivotal clinical trial data, current indications for targeted therapies, and major challenges to effective precision treatment, including adaptive resistance and blood-brain barrier penetration. Sporadic pediatric low-grade gliomas (pLGGs) are characterized by alterations activating the RAS-mitogen-activated protein kinase (MAPK) pathway, particularly BRAF fusions and V600E mutations, enabling the integration of targeted therapies into frontline treatment. Among high-grade tumors, infant-type hemispheric gliomas represent a favorable, fusion-driven subgroup characterized by recurrent receptor tyrosine kinase alterations involving ALK, NTRK1/2/3, ROS1, and MET, with remarkable sensitivity to selective inhibitors. In contrast, pediatric-type diffuse high-grade gliomas (pHGGs) and diffuse midline gliomas (DMGs) in older children remain highly refractory and are frequently driven by epigenetic dysregulation associated with histone H3 G34 and H3 K27 alterations. Targeted therapies have an expanding role in the management of pediatric low- and high-grade gliomas. Further research is particularly needed for pHGGs and DMGs, where outcomes remain unsatisfactory and effective therapeutic options are limited.

PMID 42762133
Read full article →
PubMedIndustrial & engineering chemistry research2026-09-19

Performance Assessment of a Membrane Gas Absorption (MGA) Process for Biogas Upgrading with Potassium-Based Solvents.

Grekou Triantafyllia T, Lazaridou Nikoleta N, Pagliaro Maria V MV, Miller Hamish Andrew HA et al.

Global energy instability has increased interest in biomethane production through biogas upgrading as a renewable alternative to natural gas. This study experimentally investigated membrane gas absorption (MGA) for CO2 capture using aqueous potassium hydroxide (KOH) and potassium carbonate (K2CO3) in a hydrophobic polypropylene hollow fiber membrane contactor under once-through and recycle operating modes. KOH demonstrated faster reaction kinetics and superior mass transfer performance, whereas K2CO3 exhibited slower but steadier CO2 absorption behavior. Under recycle mode operation, both absorbents reached a comparable saturation capacity of approximately 1 mol of CO2 per mol of absorbent despite their different absorption profiles. The membrane showed no measurable performance decline or morphological changes, confirming good membrane stability and compatibility with both solvents. The results demonstrate the potential of MGA as an effective and flexible approach for small- to medium-scale decentralized biogas upgrading using alkaline solvents with improved chemical stability, lower toxicity, and potential economic advantages over conventional amine-based absorbents.

PMID 42761739
Read full article →
PubMedEnvironmental science and pollution research international2026-09-19

Emerging two-dimensional materials in PFAS remediation: a comprehensive review of adsorption mechanisms and efficiency.

Adnan Taghreed M TM, Hasan Manar Banwan MB, Jweeg Muhsin J MJ, Hamad Alaa J AJ et al.

Perfluoroalkyl and polyfluoroalkyl substances (PFAS) are extensively applied in both industrial and consumer products. To overcome the drawbacks of traditional treatment techniques, researchers are increasingly exploring two-dimensional (2D) materials as innovative solutions for PFAS remediation. Due to their distinctive properties, 2D materials exhibit significant potential for environmental remediation applications. This review examines a range of 2D materials, including graphene, MXenes, 2D metal-organic frameworks (MOFs), covalent organic frameworks (COFs), layered double hydroxides (LDHs), phosphorene, and hexagonal boron nitride (h-BN). It highlights their efficacy in adsorbing PFAS from water. By exploring the results of performance from available literature, it can be stated that graphene has been among the best-performing materials for a number of reasons. These reasons include its extensive surface area and the ability to alter its surface chemistry to capture PFAS via adsorption. Due to their structural and electrochemical stability, as well as the capacity to remove PFAS from waters of different matrices/conditions, MXenes (although with a limited number of reports) were the second-best-performing material. In addition, among the 2D MOFs and COFs, the ability to adsorb PFAS efficiently was attributed to their engineered porous frameworks. LDHs also have an effective surface for capturing PFAS in the waters because their positively charged metal hydroxide layers and PFAS are negatively charged. h-BN, which possesses a graphene-like layered architecture and provides remarkable chemical and thermal stability. Phosphorene, although less studied, exhibits a highly reactive surface owing to its high electron density, suggesting significant potential for adsorption applications.

PMID 42760469
Read full article →
PubMedJournal of colloid and interface science2026-09-19

Visible light-driven sustainable peroxymonosulfate activation over Mn(III)-rich NiMn-LDH for deep degradation of emerging organic contaminants at high salinity condition: Mechanistic insights and toxicity assessment.

Xia Xiyuan X, Wang Lan L, Cheng Qian Q, Hou Chen C et al.

Developing high-performance and stable heterogeneous catalysts for the continuous activation of peroxymonosulfate (PMS) is crucial to remediate emerging organic contaminants (EOCs) in complex aqueous environments. Herein, we successfully construct Mn(III)-rich NiMn layered double hydroxide (Ni1.5Mn1-LDH-5) with fast electron transfer rate to efficiently catalyze PMS for the generation of multitudinous reactive species under visible-light irradiation, enabling fast degradation of electron-rich EOCs. The Mn(III)-initiated photo-assisted Fenton-like system achieves near-100% bisphenol A (BPA) removal within 1 min and a high mineralization of 81.83% within 60 min, substantially surpassing the most state-of-the-art catalyst/PMS systems. Multiple experimental results suggest that reactive Mn(III) species dominate the PMS activation, enabling simultaneous PMS oxidation and reduction; Ni sites act as electron mediators to substantially promote the photo-excited electrons transport for Mn(IV)/Mn(III) cycle and accelerate electron transfer between Mn sites and PMS molecules. These attributes synergistically enhance the valence cycling of [Mn(II) ↔ Mn(III) ↔ Mn(IV)], thereby creating continuous PMS activation sites and boosting the production of SO4•-/•OH, and 1O2. Furthermore, NiMn-LDH maintains outstanding contaminants removing performance under high salinity conditions, and shows excellent cyclic stability with completed degradation of BPA for 15 h continuous operation. The toxicity assessment and sprout growth experiment demonstrate that this system achieves deep mineralization and even complete detoxification of organic contaminants. This work yields new insight into developing high-performance catalysts for efficient remediation of refractory organic contaminants in complex water matrices.

PMID 42762674
Read full article →
PubMedZhonghua yi xue za zhi2026-09-19

[Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)].

Oncology Society of Chinese Medical Association

To further standardize the prevention and management of lung cancer in China, improve the level of diagnosis and treatment, enhance patient prognosis, and provide evidence-based professional recommendations for clinical practitioners at all levels, the Oncology Society of Chinese Medical Association organized experts from respiratory medicine, medical oncology, thoracic surgery, radiation oncology, radiology, and pathology to develop the "Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)" through a consensus conference. Compared with the 2025 edition, the 2026 edition incorporates updates and refinements in several aspects. In the lung cancer screening section, quality control requirements for low-dose computed tomography screening have been further detailed, and the introduction and scope of application of opportunistic screening and artificial intelligence technologies in lung cancer screening have been added. In the pathology section, on the basis of the latest clinical research findings and newly approved indications by the National Medical Products Administration (NMPA), the recommendations for molecular pathological testing have been supplemented, with several new gene testing-related recommendations added. In the treatment section, perioperative neoadjuvant and adjuvant treatment regimens for non-small cell lung cancer have been updated according to newly approved drugs and indications; additional options for consolidation immunotherapy after concurrent or sequential chemoradiotherapy for unresectable stage Ⅲ non-small cell lung cancer have been incorporated; and first-line and subsequent-line treatment strategies for patients with advanced epidermal growth factor receptor (EGFR)-mutations have been further refined. In addition, treatment recommendations for patients with non-small cell lung cancer harboring molecular subtypes such as anaplastic lymphoma kinase (ALK) fusion, KRAS G12C mutation, human epidermal growth factor receptor 2 (HER-2) mutations, and MET amplification have also been updated based on the approval of novel agents. This guideline adheres to NMPA-approved indications as the core principle, is grounded in drugs practically available in China and integrates recommendations from international guidelines as well as the current status of clinical practice in China. It synthesizes the latest evidence-based medical advances in recent years covering lung cancer screening, diagnosis, pathology, genetic testing, immunologic and molecular biomarker testing, treatment modalities, and follow-up, with the aim of providing reasonable and practical recommendations for clinicians at all levels, as well as professionals in radiology, laboratory medicine, and related disciplines.

PMID 42763208
Read full article →
PubMedFrontiers in oncology2026-09-18

Analysis of clinical features and outcomes in a Chinese cohort with ALK fusion across pan-cancer: a retrospective study.

Zhang Meng M, Feng Yi Y, Du Xue X, Qu Changda C et al.

ALK fusions are validated oncogenic drivers, yet their molecular heterogeneity and therapeutic implications remain poorly characterized. This study defined the landscape of ALK fusion partners, EML4-ALK variants, and co-mutations and their impact on treatment responses in a large Chinese pan-cancer cohort. We retrospectively analyzed 16,335 consecutive pan-cancer patients via next-generation sequencing to identify ALK fusions. Clinical characteristics, fusion partners, co-mutations, and treatment responses were evaluated. Progression-free survival (PFS) was assessed in advanced non-small cell lung cancer (NSCLC) patients receiving first-line ALK tyrosine kinase inhibitors (TKIs), stratified by EML4-ALK variants and TP53 status. ALK fusions were detected in 321 patients. NSCLC accounted for 93.1% (299/321), predominantly adenocarcinomas (292/299, 97.7%). EML4 was the predominant fusion partner, accounting for 92.1% of ALK fusion in lung adenocarcinoma but only 27.3% in extrapulmonary tumors. Conversely, non-EML4 fusions were more frequent in extrapulmonary tumors (72.7%). Among 13 evaluable advanced-stage patients with rare ALK fusions, 10 achieved objective response (76.9%). In 161 advanced or recurrent NSCLC patients treated with ALK-TKIs, the median PFS was 28.2 months. Patients with long EML4-ALK variants had superior PFS than those with short variants when treated with second-generation TKIs (55.7 vs. 27.1 months; p = 0.019). TP53 co-mutations were associated with shorter PFS in the first-generation TKI subgroup (5.6 vs. 21.4 months; p = 0.009). While ALK fusion partners exhibit tumor-type specificity, ALK-TKIs demonstrate potential efficacy in rare fusions though these findings are exploratory and need validation. Short EML4-ALK variants and TP53 co-mutation are associated with poorer TKI efficacy.

PMID 42755602
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about aluminium hydroxide